Novoxar, Inc. is a wholly-owned subsidiary of twoXAR, Inc. It was formed in connection with the twoXAR-KemPharm collaboration and has executed a research and license agreement with KemPharm, Inc.


    Read the press release at www.twoxar.com/news-and-events.


    twoXAR is an artificial intelligence-driven biopharmaceutical company that leverages its computational platform to identify promising drug candidates, de-risk the opportunities through preclinical studies, and progress drug product candidates into the clinic through industry partnerships. Based in Mountain View, California, the twoXAR team includes experts in drug discovery and development, biomedical informatics, computational biology, data science and software development. Investors in twoXAR include SoftBank Ventures, the Andreessen Horowitz Bio Fund, OS Fund, CLI Ventures, and the Stanford-StartX Fund. For more information, please visit www.twoXAR.com.